Patents by Inventor Bret Lee Bostwick

Bret Lee Bostwick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PRION PROTEIN (PRNP) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240124882
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a prion protein (PRNP) gene, as well as methods of inhibiting expression of a PRNP gene and methods of treating subjects having a PRNP-associated disease or disorder, e.g., Prion diseases, using such dsRNAi agents and compositions.
    Type: Application
    Filed: August 22, 2023
    Publication date: April 18, 2024
    Inventors: Haiyan Peng, Bret Lee Bostwick, James D. McIninch, Mark K. Schlegel, Adam Castoreno, Tuyen M. Nguyen
  • G PROTEIN-COUPLED RECEPTOR 75 (GPR75) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230392156
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the G-protein coupled receptor 75 (GPR75) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a GPR75 gene and to methods of treating or preventing a GPR75-associated disease, such as a body weight disorder, e.g., obesity, in a subject.
    Type: Application
    Filed: April 3, 2023
    Publication date: December 7, 2023
    Applicants: Alnylam Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc.
    Inventors: James D. McIninch, Bret Lee Bostwick, Adam Castoreno
  • APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230193268
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting an APOE gene, as well as methods of inhibiting expression of an APOE gene and methods of treating subjects having an APOE-associated neurodegenerative disease or disorder, e.g., Alzheimer's disease and Parkinson's disease, using such dsRNAi agents and compositions.
    Type: Application
    Filed: October 27, 2022
    Publication date: June 22, 2023
    Inventors: Bret Lee Bostwick, Haiyan Peng, James D. McIninch, Adam Castoreno, Mark K. Schlegel
  • COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    Publication number: 20230136552
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene for methods of using such iRNA to inhibit expression of C5 and to treat subjects having ALS.
    Type: Application
    Filed: July 26, 2022
    Publication date: May 4, 2023
    Inventors: Anna Borodovsky, Bret Lee Bostwick
  • SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230032974
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting an RPS25 gene, as well as methods of inhibiting expression of an RPS25 gene and methods of treating subjects having an RPS25-associated disease or disorder, such as a nucleotide repeat expansion disorder, e.g., c9orf72 amyotrophic lateral sclerosis (ALS)/frontotemporal demential (FTD) and Huntington-Like Syndrome Due To C9orf72 Expansions, using such dsRNAi agents and compositions.
    Type: Application
    Filed: February 10, 2022
    Publication date: February 2, 2023
    Inventors: Bret Lee Bostwick, Mangala Meenakshi Soundarapandian, James D. McIninch, Gregory Hinkle
  • HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220380762
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a Huntingtin (HTT) gene, e.g., exon 1 of an HTT gene, as well as methods of inhibiting expression of an HTT gene and methods of treating subjects having an HTT-associated disease or disorder, e.g., Huntington's disease, using such dsRNAi agents and compositions.
    Type: Application
    Filed: April 28, 2022
    Publication date: December 1, 2022
    Inventors: Mangala Meenakshi Soundarapandian, James D. McIninch, Bret Lee Bostwick, Mark K. Schlegel, Adam Castoreno, Jeffrey Zuber